Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) shares reached a new 52-week high on Friday . The company traded as high as $9.57 and last traded at $9.37, with a volume of 237018 shares. The stock had previously closed at $9.13.
Analysts Set New Price Targets
ZVRA has been the topic of a number of research reports. Canaccord Genuity Group dropped their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, November 14th. Maxim Group boosted their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, September 24th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zevra Therapeutics in a research report on Friday, October 11th. JMP Securities started coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They set an "outperform" rating and a $17.00 price objective on the stock. Finally, William Blair raised shares of Zevra Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $21.00.
Check Out Our Latest Stock Analysis on ZVRA
Zevra Therapeutics Stock Up 4.3 %
The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm's 50 day moving average price is $8.16 and its two-hundred day moving average price is $6.60. The company has a market capitalization of $508.18 million, a P/E ratio of -4.63 and a beta of 1.93.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. During the same period in the previous year, the company posted ($0.40) EPS. Equities research analysts forecast that Zevra Therapeutics, Inc. will post -1.92 EPS for the current year.
Hedge Funds Weigh In On Zevra Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of ZVRA. Sanctuary Advisors LLC acquired a new position in shares of Zevra Therapeutics during the 2nd quarter worth approximately $474,000. Jacobs Levy Equity Management Inc. lifted its position in Zevra Therapeutics by 102.4% during the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company's stock worth $201,000 after acquiring an additional 17,557 shares during the last quarter. Simplify Asset Management Inc. bought a new stake in shares of Zevra Therapeutics during the third quarter worth approximately $833,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Zevra Therapeutics during the 1st quarter valued at $64,000. Finally, Vanguard Group Inc. raised its stake in Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company's stock valued at $9,883,000 after purchasing an additional 58,866 shares in the last quarter. Institutional investors own 35.03% of the company's stock.
Zevra Therapeutics Company Profile
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
